SPRY

ARS Pharmaceuticals
SPRY

Last Price

Financial Snapshot

gainify

Market Data

Market Cap
$1.39B
EV
$1.14B
Shares Outstanding
106.18M
Beta
0.94

Wall Street View

Analyst Rating
BUY
Analyst Target Price
$31.60
P/E 2025E
-
P/Revenue 2025E
16.72x

Price Dynamic

Price

%

1M

3M

6M

1Y

3Y

5Y

Peers

gainify

About ARS Pharmaceuticals, Inc.

gainify
SPRY

ARS Pharmaceuticals, Inc.

SPRY

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, includin...

Sector

Healthcare

Industry

Biotechnology

CEO

Lowenthal, Richard

Employees

158

IPO Date

2020-12-04

Headquarters

11682 El Camino Real, Suite 120, San Diego, California, 92130, United States

gainify
mailcontactcontact
powered-by-sp

NEWSLETTER

COMPANY

© Copyright 2025, All Rights Reserved